Malcolm VandenBurg

Malcolm VandenBurg is an English doctor involved in drug research, sexual health, legal advice and stress management. He has contributed to the type of drugs currently available to patients and to how medical professionals practice.

He has undertaken various studies and research including diagnosis and management of patients with congestive heart failure, enzyme inhibitors and preventing fraud and studies of quadruple therapy for resistant hypertension.

Career

Qualified in St Bartholomew’s Hospital in 1973 with a BSc in Physiology. Hospital training included sexual health, urology, cardiology, gastroenterology, rheumatology, neurology and respiratory medicine.^{[1][self-published source?]}

Lectured in medicine, as an Honorary Senior Registrar at the Professorial Medicine Unit at the London Hospital where he continued his training in General Internal Medicine, specialising in Sexual Health, Cardiology and Nephrology.^{[1][self-published source?]}

Fellow Royal College of Physicians, American College of Clinical Pharmacology, Faculty of Pharmaceutical Medicine and Member of the International Stress Management Association.^{[1][self-published source?]}

Established the London Hospital Hypertension Clinic.^[2]

Appointed as a member of the Council of the British Medicinal Cannabis Register.^[3]

Other positions

Director of Cardiovascular Research, Department of Cardiology, Old Church Hospital Romford (1984–1996).^{[1][self-published source?]} Director of Clinical Research, Merck Sharpe & Dohme (1980–1984).^{[1][self-published source?]} Honorary Lecturer in Clinical Pharmacology, St. Bartholomew's Hospital (1980–1990),^{[1][self-published source?]} Chief Scientific Officer of The Clinical Research Organisation,^{[1][self-published source?]} MCRC Ltd (1984–1994) and Chief Executive Officer of The Global Research Consultancy IBRD - Rostrum Inc. (1995–1998).

Co-ordinated clinical drug development programmes for in excess of 30 pharmaceutical products in every medical and therapeutic area. Authored pharmaceutical product licencing reports for over 20 products. Also Supervising Physician for four New Drug Applications to the U.S. Food and Drug Administration (FDA).^{[1][self-published source?]}

Drug development programmes

Responsible for the development of numerous new drugs and medicines , incorporating initial study and later developmental stages.

Phase Iia studies include Go/No-go studies for a potassium channel activator, NSAID’s, Calcium sensitiser, Oral inotropes for CHF, Insulin sensitiser, Anti-nausea drugs, Anti-anginal, Drugs for pain, Anti-rheumatic disease modifier, Peripheral vascular disease, Obsessive-compulsive disorder, Homeopathic for flu, Anti-depressant, Irritable Bowel Syndrome, Anti-asthmatic, Alcohol abuse, H2 antagonist, Anti-infectives, Drugs for hypertension (Heart failure, Angina and Arrhythmias) and impotence.

Phase III studies he has undertaken include, Three converting enzyme inhibitors, Beta-blocker, H2 antagonist, Anti-cancer agents, Anti-infectives, AIDS therapy, Potassium channel activator, Alcohol Addiction, Non-steroidial anti-inflammatory drugs, Parkinson’s therapy, Vaccines for Hepatitis B, Wound dressings, Raised IOP.

Phase IV programmes cover Anti-hypertensives, Antibiotics, H2 antagonist, Non-steroidial anti-inflammatory drugs, Anti-anginal, Anti-Bleeding Compounds and Diuretic.

Publications (peer reviewed)

Malcolm Vandenburg has published over 120 peer reviewed articles on the effects of pharmaceutical medicines based on his work at The London Hospital Hypertension Clinic and subsequent appointments.

Publications include:

• Andrews, D; Gouda, M S; Higgins, S; Johnson, P; Williams, A; Vandenburg, M (2002). "A comparative study of a new wireless continuous cardiorespiratory monitor for the diagnosis and management of patients with congestive heart failure at home". Journal of Telemedicine and Telecare 8 (2): 101–3. doi:10.1258/135763302320302235. PMID 12217157. 
• Johnson, P; Andrews, DC; Wells, S; De Lusignan, S; Robinson, J; Vandenburg, M (2001). "The use of a new continuous wireless cardiorespiratory telemonitoring system by elderly patients at home". Journal of telemedicine and telecare 7 Suppl 1: 76–7. PMID 11576502. 
• Dews, I; Vandenburg, M (2001). "A 24-week dose-titration study of the angiotensin-converting enzyme inhibitor imidapril in the treatment of mild-to-moderate essential hypertension in the elderly". The Journal of international medical research 29 (2): 100–7. PMID 11393342. 
• De Lusignan, S; Althans, A; Wells, S; Johnson, P; Vandenburg, M; Robinson, J (2000). "A pilot study of radiotelemetry for continuous cardiopulmonary monitoring of patients at home". Journal of telemedicine and telecare 6 Suppl 1: S119–22. PMID 10793994. 

Publications (other)

As well as peer reviewed publications Malcolm Vandenburg has also written extensively in commercial publicaitons. Articles include:

• Personal Development Training, Pharmaceutical Times, September 1994, p26-27,
• Self Confidence for Success, Pharmaceutical Marketing, September 1994, p41-42,
• 5 Rs for Keeping Positive Under Pressure, Business Now, August 1997, issue 94,
• Positive Under Pressure, Training Officer, December 1998, Vol 34 No 10, p303-305,
• Grace Under Pressure Sales Director, November 1998, p63,
• Is your job a health hazard?, Health & Fitness, May 2000, 51,
• Be Positive Under Pressure Business Executive, Winter 2000, p6-8
• The Stress-free Life Plan Family Circle, November 2001, p58–60.

Books

• Positive Under Pressure jointly authored with Gael Lindenfield, published by Avenue Books (24 April 2006)
• Dilemmas and Solutions in Global Drug Development, published by Brookwood Medical Publications (January 2003)
• Good Clinical Practice for Investigators, ROSTRUM Publications (July 1990)

References

1. ^ ^{a b c d e f g h} "Malcolm VandenBurg online CV". Malcolmvandenburg.co.uk. http://www.malcolmvandenburg.co.uk/DrVandenBurgCV.php. Retrieved 2011-09-27. 
2. ^ "BMJ Careers - A controversial career". Careers.bmj.com. 2009-08-06. http://careers.bmj.com/careers/advice/view-article.html?id=20000298. Retrieved 2011-09-27. 
3. ^ Peter Reynolds. "European Parliament – Public Hearing On Cannabis Regulation « Peter Reynolds". Webcache.googleusercontent.com. http://webcache.googleusercontent.com/search?q=cache:Fe88X2RTOJoJ:peterreynolds.wordpress.com/2010/11/27/european-parliament-public-hearing-on-cannabis-regulation/+%22malcolm+vandenburg%22&cd=30&hl=en&ct=clnk&gl=uk. Retrieved 2011-09-27. 

External links

• Click here to find out more about Positive Under Pressure. Published by Avenue Books (24 April 2006)
• Click here for Daily Mail article 1284997
• Dilemmas and Solutions in Global Drug Development published by Brookwood Medical Publications (January 2003)
• Malcolm VandenBurg

Persondata
Name	Malcolm VandenBurg
Alternative names	VandenBurg MJ
Short description	English doctor, specialising in sexual health, stress management and legal issues
Date of birth	21st December 1948
Place of birth	England
Date of death
Place of death